NCT00089713终止2 期
Effect of ALT-711 in Combination With Fixed-Dose Hydrochlorothiazide Therapy on Systolic Blood Pressure in Hypertensive Patients
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 392
- 试验地点
- 2
研究概览
简要总结
This study comprises a 3- to 6-week hydrochlorothiazide run in phase, followed by a 12 week double-blind treatment phase, followed by a 2 week single-blind follow-up hydrochlorothiazide treatment phase. The combined total duration of patient participation is approximately 17-20 weeks. Four double-blind treatment groups approximately equal in size (98) will comprise the study population: placebo or various alagebrium dose groups (10, 50, or 150 mg/day).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 45 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men or women at least 45 years of age with uncontrolled systolic hypertension measured by office cuff and by an ambulatory blood pressure monitoring device
- •Willingness to be taken off any current antihypertensive treatment to be placed on hydrochlorothiazide in combination with study medication.
排除标准
- •Any significant history, systemic illnesses, or medical condition(s) that could lead to difficulty complying with the protocol or that could confound interpretation of the data.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in HypertensionEssential HypertensionNCT00902538Daiichi Sankyo2,204
已完成
1 期
A Drug to Drug Interaction Study of Sotagliflozin With HydrochlorothiazideType 2 Diabetes MellitusNCT03387657Sanofi16
已完成
2 期
3 x 3 Factorial Trial of Telmisartan and Hydrochlorothiazide in Patients With Essential HypertensionHypertensionNCT00153049Boehringer Ingelheim583
已完成
3 期
Telmisartan With or Without Hydrochlorothiazide in Patients With Mild-to-moderate HypertensionHypertensionNCT02177435Boehringer Ingelheim491
已完成
1 期
A Pharmacodynamics, Pharmacokinetics, and Safety Study of Hydrochlorothiazide and Canagliflozin in Healthy VolunteersHealthyNCT01294631Johnson & Johnson Pharmaceutical Research & Development, L.L.C.30
